Search results
Found 6219 matches for
Oxford University collaborate with Bvlgari to fight COVID-19 and future pandemics
Clinical Trials Coronavirus COVID-19 General
17 June 2020
Bvlgari, the Italian luxury brand, has today announced plans to support research into COVID-19 and vaccine development at Oxford University.
Children show increase in mental health difficulties over COVID-19 lockdown
Coronavirus COVID-19 General Research
16 June 2020
More than 10,000 parents have now taken part in the Co-SPACE (COVID-19 Supporting Parents, Adolescents, and Children in Epidemics) survey led by experts at the University of Oxford.
Dexamethasone reduces death in hospitalised patients with severe respiratory
Clinical Trials Coronavirus COVID-19 General Research
16 June 2020
In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK.
New partnership aims to significantly reduce the incidence of hip and vertebral fractures
General Innovation Research
16 June 2020
The Capture the Fracture Partnership aims to prevent 250 million fractures by 2025 and combat the global public health burden of osteoporosis.
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit
Clinical Trials Coronavirus COVID-19 General
15 June 2020
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.
Oxford to collaborate on AI algorithms to help predict COVID-19 severity in patients
Coronavirus COVID-19 General Research
15 June 2020
The University of Oxford-led National Consortium of Intelligent Medical Imaging (NCIMI) in the UK is collaborating with GE Healthcare to develop and test algorithms to aid in the diagnosis and management of COVID-19 pneumonia.
Oxford researchers lead international study on effects of COVID-19 on sleep
Coronavirus COVID-19 General Research
15 June 2020
An international group of researchers led by Professor Colin Espie from the Nuffield Department of Clinical Neurosciences at the University of Oxford is investigating the impact of the COVID-19 pandemic on sleep and daily rhythms in adults.
Serum iron may be useful biomarker to identify COVID-19 disease severity
Coronavirus COVID-19 General Research
12 June 2020
A new study led by Radcliffe Department of Medicine researchers analyses iron levels in COVID-19 intensive care patients to find that patients with very low levels of iron had severe respiratory failure.
Oxford-Sri Lanka study to compare COVID-19 immune response
Coronavirus COVID-19 General Research
12 June 2020
A new study builds on a successful collaboration and will compare T cell and antibody responses to uncover the role of ‘background’ immunity to virus strains already in circulation, including infections with similar coronaviruses.
Women are majorly under-represented in COVID-19 research authorship
Coronavirus COVID-19 General Research
12 June 2020
New research from The George Institute for Global Health at the University of Oxford has found significant gender bias in research authorship relating to COVID-19, which means that women’s views are not equally shaping the response to the pandemic.
Transformational gift to support Oxford’s newest graduate college
General
11 June 2020
Oxford University has received a landmark £80 million donation from the Reuben Foundation that will transform Oxford’s newest college and establish a major new scholarship programme for graduate and undergraduate students.
Oxford researchers awarded funding to unlock disease biology
Awards and Appointments General Research
10 June 2020
Oxford Structural Genomics Consortium (SGC) is a key member of a new EUbOPEN consortium which has been awarded funding from the Innovative Medicines Initiative to develop openly available chemical tools for understanding human biology.
CATALYST trial: Oxford leads part of major COVID-19 drugs trial
Clinical Trials Coronavirus COVID-19 General
10 June 2020
As part of the UK NIHR multi-arm, multi-stage CATALYST Trial, researchers at the University of Oxford will investigate whether administering the anti-inflammatory drug infliximab to patients with COVID-19 can prevent progression to respiratory failure or death.
Imaging platform gets grant to teach frontline staff how to recognise COVID-19
Coronavirus COVID-19 General Innovation
8 June 2020
A team of radiologists and radiographers at Oxford University Hospitals and University of Oxford's Department of Oncology has secured a grant to customise a teaching platform to educate frontline NHS staff to diagnose COVID-19 using chest X-rays and CT scans.
The neurobiology of social distance: why loneliness may be the biggest threat to survival
Coronavirus COVID-19 General Research
8 June 2020
Never before have we experienced social isolation on a massive scale as we have during the evolving COVID-19 pandemic.
New resources on talking to children about illness and death during the COVID-19 pandemic
Coronavirus COVID-19 General Research
5 June 2020
The news that children currenty face may seem almost unspeakable. But, together, we must find words, and ways, to give voice to their experience and prevent millions of children struggling with their fears and uncertainty alone.
No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
Clinical Trials Coronavirus COVID-19 General Research
5 June 2020
A new statement has been released from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine.
Clinical trials on hydroxychloroquine/ chloroquine in COVID-19. Statement in response to damaging recent events
Clinical Trials Coronavirus COVID-19 General Research
5 June 2020
On 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then a little over an hour later the New England Journal of Medicine, retracted studies that were based on inaccessible data, provided by the Surgisphere corporation. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. Here is MORU’s statement in response to these events.